corporate overview


investors & media


investors & media

Investor Relations Home

Rigel currently has the following product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP and initiating a Phase 2 clinical trial for IgA nephropathy (IgAN); R348, a topical JAK/SYK inhibitor, in a Phase 2 clinical trial for dry eye in ocular graft-versus-host disease (GvHD); two oncology product candidates in Phase 1 development with partners BerGenBio AG and Daiichi; and two preclinical programs with partners AstraZeneca for R256 in asthma and Bristol-Myers Squibb for TGF beta inhibitors in immuno-oncology.

Stock Quote
RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Up 0.18 (5.04%)
Data as of 04/01/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
2015 Proxy Statement - PDF 
2015 Proxy Statement
2014 Annual Report - PDF 
2014 Annual Report
Financial Tear Sheet - PDF 
Financial Tear Sheet
Recent NewsMore >>
03/03/15Rigel Announces Fourth Quarter and Year End 2014 Financial Results
SOUTH SAN FRANCISCO, Calif., March 3, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Rigel reported a net loss of $22.3 million, or $0.25 per share, compared to a net loss of $16.9 million, or $0.19 per share, in the fourth quarter of 2013. Weighted average shares outstanding for the fourth quarters of 2014 and 2013 were 87.8 million and 87.4 million, res... 
Printer Friendly Version
02/23/15Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications
SOUTH SAN FRANCISCO, Calif. and NEW YORK, February 23, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability ... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitleRemind MePrior to Event
June 1, 2015 - Jun 04 15
Rigel Pharmaceuticals Inc. at Jefferies 2015 Healthcare Conference Presentation
Enter your e-mail address 
Most Viewed Links
Updated 01/31/15
1.SEC Filings
2.Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference
3.Rigel Initiates Phase 3 Studies of Fostamatinib in ITP
4.Current Financial Reports
5.Rigel Announces Executive Management Changes
* Data collected 01/23/15 - 01/30/15
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
© 2014 Rigel  |  privacy  |  disclaimer  | Follow Us On:contact us | site map |  search    Search